Novartis's Phase III Program For MS Agent FTY720 Delayed By Safety Request From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm previously had projected a mid-year start for Phase III studies of the oral multiple sclerosis treatment. Novartis says the revised timeframe will allow for an FDA-requested safety analysis relating to FTY720's use in renal transplantation.